32nd week of 2022 patent applcation highlights part 26 |
Patent application number | Title | Published |
20220251096 | 7,8-DIHYDRO-4H-PYRAZOLO[4,3-c]AZEPINE-6-ONE COMPOUNDS - Disclosed herein are compounds of Formula I: wherein R | 2022-08-11 |
20220251097 | MOLECULES AND METHODS RELATED TO TREATMENT OF UNCONTROLLED CELLULAR PROLIFERATION - The present disclosure relates to chemical compounds that modulate cellular proliferation for the treatment of uncontrolled cellular proliferation disorders (such as cancer), pharmaceutical compositions containing such compounds, and their use in treatment. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2022-08-11 |
20220251098 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE - The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted bicyclic heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. | 2022-08-11 |
20220251099 | MODULATORS OF ION CHANNEL RECEPTORS AND USES THEREOF - Compounds useful in the modulation of ion channel activity in cells are disclosed herein. This disclosure also relates to use of these compounds in the treatment of pain, and pharmaceutical compositions containing these compounds and methods for their preparation. | 2022-08-11 |
20220251100 | KIDNEY-TARGETED EPOXYEICOSATRIENOIC ACID (EET) ANALOGS - Described here are EET analogs conjugated to folate receptor ligands such as folic acid or folic acid analogs recognized by and selectively bound by folate receptors and other folate binding proteins and the use of such conjugated EET analogs for targeted delivery of therapeutic agents to folate-receptor bearing cell populations. More particularly, provided herein are EET analogs conjugated to folate receptor ligands and uses of such conjugated EET analogs as kidney targeted therapeutics. | 2022-08-11 |
20220251101 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2- -TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF - The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and various spondyloarthritic conditions, including types of axial spondyloarthritis (axSpA)), kits, methods of synthesis, and products-by-process. In various aspects, provided are methods for treating active non-radiographic axSpA (nr-axSpA) and methods for treating active ankylosing spondylitis (AS). | 2022-08-11 |
20220251102 | ALDOKETO REDUCTASE INHIBITORS AND USES THEREOF - An aldoketo reductase inhibitor includes a xanthene analogue. | 2022-08-11 |
20220251103 | Compositions and Methods for Treating Atopic Dermatitis - A method of improving skin health and condition comprising the application of select isohexides to the skin. | 2022-08-11 |
20220251104 | AROMATIC COMPOUNDS FOR USE IN ACTIVATING HEMATOPOIETIC STEM AND PROGENITOR CELLS - Disclosed herein are new aromatic compounds, compositions that include one or more aromatic compounds, and methods of synthesizing the same. Also disclosed herein are methods of increasing and/or expanding cells, including stem cells, hematopoietic stem cells, progenitor cells, and placenta or cord blood-derived cells, with one or more compounds or compositions described herein. Also disclosed herein are methods of increasing and/or expanding differentiated hematopoietic cells with one or more compounds or compositions described herein. | 2022-08-11 |
20220251105 | METHODS OF TREATING A MK2-MEDIATED DISORDER - The present invention provides methods of treating, stabilizing or lessening the severity or progression of one or more diseases or conditions associated with MK2. | 2022-08-11 |
20220251106 | ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE - An organic compound, represented by formula [1] or [2], suitably used for a thermally activated delayed fluorescent device: | 2022-08-11 |
20220251107 | PROCESS FOR PREPARING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVE AND CRYSTAL THEREOF - The present invention provides a process for preparing a compound of the formula (II): | 2022-08-11 |
20220251108 | NON-IMMUNOSUPPRESSIVE FK506 ANALOGS AND USE THEREOF - The present invention provides a new class of non-immunosupressive FK506 analogs which are FKBP-selective, small-molecule BMP agonists with modest potency therepeutics for tissue repair and regeneration. Also disclosed herein are methods for making and use of these compounds. | 2022-08-11 |
20220251109 | OXAAZAQUINAZOLINE-7(8H)-KETONE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF - An oxaazaquinazolin-7(8H)-ketone compound with a selective inhibition effect on KRAS gene mutation and pharmaceutically acceptable salts thereof, stereoisomers, solvent compounds or prodrugs (as shown in formula I or formula II, see the details of the definition to each group in the formulas in the specification), as well as the pharmaceutical composition containing the compound, and the application thereof in preparation of cancer medicine. | 2022-08-11 |
20220251110 | CGRP ANTAGONIST COMPOUNDS - The disclosures herein relate to novel compounds of Formula (1a): and salts thereof, wherein W, Z, L, R | 2022-08-11 |
20220251111 | PROCESS FOR THE PREPARATION OF AMORPHOUS MIDOSTAURIN WITH A LOW CONTENT OF RESIDUAL ORGANIC SOLVENT - The present invention relates to a process for the preparation of an amorphous form of midostaurin with a low content of residual organic solvent. | 2022-08-11 |
20220251112 | PROCESS FOR PREPARATION OF EDOXABAN - The present invention relates to process for preparation of N1-(5-Chloropyridin-2-yl)-N2-[(1S,2R,4S)-4-(N,N-dimethylcarbamoyl)-2-(5-methyl-4,5,6,7-tetrahydrothiazolo [5,4-c]pyridin-2-ylcarboxamido)cyclohexyl]oxamide p-toluene sulfonate monohydrate [edoxaban tosylate monohydrate], the compound of formula I, comprising reacting compound of formula VI with compound of formula V to obtain the compound of formula IV and further converting it to edoxaban tosylate monohydrate in an industrially feasible process. | 2022-08-11 |
20220251113 | NITROGEN-CONTAINING CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 ANTAGONISTIC EFFECT - Novel compounds having D3 receptor antagonistic activity are provided. | 2022-08-11 |
20220251114 | AZEPINES AS HBV CAPSID ASSEMBLY MODULATORS - Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of CAM1. Such compounds are represented by Formula (I) as follows: | 2022-08-11 |
20220251115 | METHODS FOR PREPARING CATLAYST PRECURSOR MATERIALS - Methods for preparing a catalyst precursor material from dihalo-substituted metalloids are provided. The methods In include mixing a first solution of a halogenated alkane, at least one solvent, and a first component selected from a dihalo-substituted-group-14 metalloid or an organolithium reagent in a first reaction zone. Continuously adding the first solution to a second reaction zone, and continuously adding a second solution to the second reaction zone. The second solution including at least one solvent and a second component of either the dihalo-substituted-group-14 metalloid or the organolithium reagent, the second component is different from the first component. Mixing the first solution and the second solution in the second reaction zone. | 2022-08-11 |
20220251116 | ALKYLBORONIC ACIDS AS ARGINASE INHIBITORS - Alkylboronic acids are provided as arginase inhibitors represented by Formula (I), or a pharmaceutically acceptable salt, stereoisomer, tautomer, or prodrug thereof and a pharmaceutical composition including compounds. | 2022-08-11 |
20220251117 | PROTEASOME INHIBITORS - The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases. | 2022-08-11 |
20220251118 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME - Provided is a heterocyclic compound of Chemical Formula 1: | 2022-08-11 |
20220251119 | PYRROMETHENE-BORON COMPLEX, COLOR CONVERSION COMPOSITION, COLOR CONVERSION FILM, LIGHT SOURCE UNIT, DISPLAY, AND ILLUMINATION DEVICE - A pyrromethene-boron complex in one aspect of the present invention is a compound with a molecular weight of 1000 or more, represented by the following general formula (1), in which at least two of R | 2022-08-11 |
20220251120 | ORGANOSILANE, IONIC ORGANOSILANE, MEMBRANE COMPOSITION, AND MEMBRANE - A dihaloorganosilane is represented by the formula (I): Each X independently represents Cl, Br, or I. Each Ar | 2022-08-11 |
20220251121 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME - A heterocyclic compound is represented by Formula 1. An organic light-emitting device includes: a first electrode; a second electrode facing the first electrode; and an organic layer between the first electrode and the second electrode and including an emission layer, wherein the organic light-emitting device includes at least one of the heterocyclic compound. | 2022-08-11 |
20220251122 | METHOD FOR PRODUCING SODIUM SALT OF PHENOL COMPOUND AND BISPHOSPHITE COMPOUND - An object of the present invention is to efficiently produce a target sodium salt from a phenol compound having two or more phenolic hydroxyl groups in a short time and at a high yield. The present invention relates to a method for producing a sodium salt of a phenol compound, including a step of mixing a phenol compound solution in which a phenol compound having two or more phenolic hydroxyl groups is dissolved and a sodium dispersion liquid in which sodium particles are dispersed. | 2022-08-11 |
20220251123 | PRODRUG MODULATORS OF THE INTEGRATED STRESS PATHWAY - Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions. | 2022-08-11 |
20220251124 | 3,5-BIS(PHENYL)-1H-HETEROARYL DERIVATIVES AS MEDICAMENTS - Compounds of general formula I are disclosed. The meaning of individual substituents is described in the claims. The compounds are useful in treatment of cancers, due to their multi-modal mechanism of action. | 2022-08-11 |
20220251125 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES - A compound including a bidentate ligand L | 2022-08-11 |
20220251126 | ANTICANCER AGENTS - The claimed subject matter provides for a method for conjugating an active material to a Pt complex. | 2022-08-11 |
20220251127 | BINDER COMPOSITION, AND PRODUCTS INCLUDING BINDER COMPOSITION - The invention relates to a method for treating lignin, wherein the method comprises the following steps: a) dissolving lignin into an aqueous composition, which contains a compound selected from the class of phenols, while keeping the temperature of the composition at 0-6° C.; and b) allowing the composition to react while keeping the temperature of the composition at 60-100° C. and the pH of the composition at a pH value of 6-14. The invention relates further to a method for producing a binder composition and to different applications thereof. | 2022-08-11 |
20220251128 | SYNTHESIS OF OLIGOMERIC COMPOUNDS COMPRISING PHOSPHOROTHIOATE DIESTER AND PHOSPHODIESTER LINKAGES - The present disclosure provides methods for synthesizing oligomeric compounds having at least one phosphorothioate diester linkage and at least one phosphate diester internucleoside linkage. In certain embodiments, the present disclosure provides oxidation reagents that produce low amounts of unwanted phosphate diester impurities in oligomeric compounds having at least one phosphorothioate diester linkage and at least one phosphate diester internucleoside linkage. | 2022-08-11 |
20220251129 | SYNTHESIS OF 3-AZIDO-3-DEOXY-D-GALACTOPYRANOSE - The present application provides a synthetic method for production of 3-azido-3-deoxy- | 2022-08-11 |
20220251130 | PURIFICATION OF OLIGOSACCHARIDES FROM A FERMENTATION BROTH BY USING FILTRATION - Disclosed is method for the purification of an oligosaccharide of interest from a fermentation broth, the method comprises providing a cell-free fermentation broth to a first filtration step using a nanofiltration membrane, thereby providing a filtrate which contains the oligosaccharide of interest; subjecting the filtrate to a second filtration step using a nanofiltration membrane, thereby providing a retentate which contains the oligosaccharide of interest; and removing salts from the retentate thereby providing a purified preparation of the oligosaccharide of interest. | 2022-08-11 |
20220251131 | PROCESS FOR THE PURIFICATION OF LACTO-N-NEOTETRAOSE - Disclosed is a process for the purification of LNnT (lacto-N-neotetraose) from a fermentation broth, the process comprises subjecting a fermentation broth to a first step of membrane filtration, thereby providing a filtrated solution, such filtrated solution is subjecting to a second step of simulated moving bed chromatography, obtaining a purified solution thereof, then subjecting this purified solution to a third step of crystallization, obtaining crystals containing the LNnT of interest, and subjecting the crystals to a fourth and final step of drying, thereby providing a highly purified powder of LNnT. | 2022-08-11 |
20220251132 | LARGE SCALE PROCESS OF 3,3'-DIDEOXY-3,3'-BIS-[4-(3-FLUOROPHENYL)-1H-1,2,3-TRIAZOL-1-YL]-1,1'-SUL- FANEDIYL-DI-BETA-D-GALACTOPYRANOSIDE - The present invention relates to a process for preparing a compound of formula (I) | 2022-08-11 |
20220251133 | METHOD OF MAKING NICOTINAMIDE RIBOFURANOSIDE SALTS, NICOTINAMIDE RIBOFURANOSIDE SALTS AS SUCH, AND USES THEREOF - The present invention relates to a method of making nicotinamide ribofuranosie salts, in particular pharmaceutically acceptable nicotinamide ribofuranoside salts. The invention further relates to the nicotinamide ribofuranoside salts as such, in particular carboxylic acid salts in crystalline form, and their use in nutritional supplements and pharmaceutical compositions. | 2022-08-11 |
20220251134 | 2,4,7-SUBSTITUTED-7-DEAZA-2'-DEOXY-2'-FLUOROARABINOSYL NUCLEOSIDE AND NUCLEOTIDE PRO-DRUGS AND USES THEREOF - The present disclosure is concerned with 2,4,7-substituted-7-deaza-2′-deoxy-2′-fluoroarabinosyl nucleoside and nucleotide prodrugs that are capable of inhibiting viral infections and methods of treating viral infections such as, for example, human immunodeficiency virus (HIV), human papillomavirus (HPV), herpes simplex virus (HSV), human cytomegalovirus (HCMV), chicken pox, infectious mononucleosis, mumps, measles, rubella, shingles, ebola, viral gastroenteritis, viral hepatitis, viral meningitis, human metapneumovirus, human parainfluenza virus type 1, parainfluenza virus type 2, parainfluenza virus type 3, respiratory syncytial virus, viral pneumonia, Chikungunya virus (CHIKV), Venezuelan equine encephalitis (VEEV), dengue (DENV), influenza, West Nile virus (WNV), zika (ZIKV), 229E, NL63, OC43, HKU1, Middle East respiratory syndrome coronavirus (MERS-CoV), severe acute respiratory syndrome coronavirus (SARS-CoV), and severe acute respiratory syndrome coronavirus disease 2019 (SARS-CoV-2), using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2022-08-11 |
20220251135 | CYCLIC DINUCLEOTIDES AS STING AGONISTS - Disclosed herein are cyclic di-nucleotide compounds and derivatives thereof that may be useful as STING agonists, and a pharmaceutical composition comprising the same. Also disclosed herein is the process for synthesis and to uses of such cyclic di-nucleotide compounds in various diseases including cancer, HIV infection and HBV infection. | 2022-08-11 |
20220251136 | MONTELUKAST ESTERS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME - The present invention relates to esters of Montelukast with corticosteroids, preferably with des-ciclesonide, triamcinolone, budesonide or flunisolide, pharmaceutical compositions containing the same and the use thereof in the treatment of several respiratory tract diseases, especially asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis. The invention further relates to the process for preparing said esters. | 2022-08-11 |
20220251137 | Temperature-controlled purification of granulocyte-colony stimulating factor - Provided herein, inter alia, are compositions, systems, and methods for the purification of granulocyte colony-stimulating factor (GCSF). Also provided are GCSF obtained by the disclosed methods and systems, pharmaceutical compositions containing the same, as well as methods for the treatment and/or prevention of a disease or health condition in an individual in need thereof. | 2022-08-11 |
20220251138 | PROCESSES FOR OBTAINING A HIGHLY CONCENTRATED ANTIBODY SOLUTION - The present invention relates to processes for obtaining a highly concentrated antibody solution. In particular, to processes for obtaining a highly concentrated therapeutic antibody solution that may be used for highly concentrated therapeutic antibody formulations, e.g. suitable for subcutaneous administration. | 2022-08-11 |
20220251140 | DPEP-1 BINDING AGENTS AND METHODS OF USE - Pharmaceutical compositions and methods of their use are provided for reducing inflammation in a subject, blocking leukocyte recruitment, inhibiting tumor metastasis, treating sepsis and preventing/reducing acute kidney injury. | 2022-08-11 |
20220251141 | IMMUNOMODULATORS - In accordance with the present disclosure, macrocyclic compounds have been discovered that bind to PD-L1 and are capable of inhibiting the interaction of PD-L1 with PD-1 and CD80. These macrocyclic compounds exhibit in vitro immunomodulatory efficacy thus making them therapeutic candidates for the treatment of various diseases including cancer and infectious diseases. | 2022-08-11 |
20220251142 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES - The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases. | 2022-08-11 |
20220251143 | NON-HYDROLYZABLE NON-CLEAVABLE, STABLE LINKERS FOR PRECISION THERAPEUTICS AND USES THEREOF - The present disclosure provides conjugate compositions comprising non-hydrolyzable, non-cleavable, stable linkers, a targeting moiety, and a therapeutic or chemotherapeutic agent. More specifically the present disclosure provides for compositions comprising non-hydrolyzable, non-cleavable, stable linkers, a somatostatin receptor (SSTR) targeting moiety, such as lanreotide, and a chemotherapeutic agent targeting microtubules, such as mertansine. Methods of using the compositions to treat cancer and other diseases are also provided. | 2022-08-11 |
20220251144 | PORCINE CIRCOVIRUS TYPE 3 IMMUNOGENIC COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME - A new species of circovirus, porcine circovirus type 3 (PCV3), was identified from sows with clinical symptoms normally associated with porcine circovirus type 2 (PCV2) infection and in aborted fetuses. Molecular and serological analyses suggest PCV3 commonly circulates in U.S. swine. The present disclosure provides immunological compositions and methods related to the production and administration of such compositions. | 2022-08-11 |
20220251145 | ADENO-ASSOCIATED VIRUS VARIANT CAPSIDS AND METHODS OF USE THEREOF - Provided herein are variant adeno-associated virus (AAV) capsid proteins having one or more modifications in amino acid sequence relative to a parental AAV capsid protein, which, when present in an AAV virion, confer increased infectivity of one or more types of muscle cells as compared to the infectivity of the muscle cells by an AAV virion comprising the unmodified parental AAV capsid protein. Also provided are recombinant AAV virions and pharmaceutical compositions thereof comprising a variant AAV capsid protein as described herein, methods of making these rAAV capsid proteins and virions, and methods for using these rAAV capsid proteins and virions in research and in clinical practice, for example in, e.g., the delivery of nucleic acid sequences to one or more muscle cells for the treatment of muscle disorders and diseases. | 2022-08-11 |
20220251146 | DNA-DEGRADING PROTEINS AND USES THEREOF - The present disclosure provides proteins, protein fragments, protein variants, fusion proteins, nucleic acids, vectors, cells, methods, kits, and compositions for cleaving DNA and/or inhibiting growth of bacterial growth using IdrD protein or a fragment thereof. In some embodiments, the disclosure provides an IdrD protein comprising a fragment of IdrD protein from | 2022-08-11 |
20220251147 | FUNCTIONALIZED UBX PROTEIN MATERIALS FOR ENHANCED PURIFICATION OF ANTIBODIES - Provided herein are methods and compositions for purifying antibodies. Purification is achieved by increasing the binding capacity of protein A chromatography by covalent attachment of a protein A domain (E, D, A, B, C), or domain Z, or a functional variant thereof, to | 2022-08-11 |
20220251148 | DE-EPITOPED ALPHA GLIADIN AND USE OF SAME FOR THE MANAGEMENT OF CELIAC DISEASE AND GLUTEN SENSITIVITY - A de-epitoped alpha gliadin is provided. Methods of generating same and uses thereof are also provided. | 2022-08-11 |
20220251149 | PEA PEPTIDE WITH AUXILIARY HYPOGLYCEMIC FUNCTION AND PREPARATION METHOD THEREOF - The present disclosure provides a pea peptide with auxiliary hypoglycemic function, and preparation method and application thereof. The pea peptide includes at least peptide segments pEE, pEK and pER in its composition; and based on a mass of the pea peptide, a content of the peptide segment pEE is ≥100.00 mg/100 g, a content of the peptide segment pEK is ≥80.00 mg/100 g and a content of the peptide segment pER is ≥90.00 mg/100 g. The pea peptide has a significant efficacy in an aspect of reducing blood glucose. | 2022-08-11 |
20220251150 | Artificial Fur and Method for Manufacturing Same - An object of the present invention is to provide an artificial fur which has a sufficient moisture-absorbing property and reduces energy required for the manufacture. The artificial fur according to this invention includes an artificial protein fiber. | 2022-08-11 |
20220251151 | KV1.3 BLOCKERS - The present invention provides novel blockers of the potassium channel Kv1.3, polynucleotides encoding them, and methods of making and using them. | 2022-08-11 |
20220251152 | COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION - The invention provides compositions including a fusion polypeptide and methods for making a fusion polypeptide that includes a degradation polypeptide and a heterologous polypeptide of interest. | 2022-08-11 |
20220251153 | PEPTIDES FOR THE TREATMENT OF RENAL DISORDERS - Provided are methods for treating a renal disorder using DJ-1 related peptides and compositions thereof. | 2022-08-11 |
20220251154 | FUSION PROTEIN AND USE THEREOF - Provided are a fusion protein, and an immunoconjugate, a nucleic acid molecule, a carrier, a composition, a cell and a preparation method related thereto, for treating tumors and/or autoimmune diseases. | 2022-08-11 |
20220251155 | COMPOSITION COMPRISING MLS-STAT3 FOR PREVENTION OR TREATMENT OF IMMUNE DISEASE - The present invention relates to: a recombinant peptide in which a Mitochondria Localization Sequence (MLS) peptide and the Signal Transducer and Activator of Transcription 3 (STAT3) are fused to each other; a recombinant vector carrying a polynucleotide coding for the recombinant peptide; and a composition comprising the recombinant peptide or the recombinant vector as an active ingredient for prevention or treatment of autoimmune disease or inflammatory disease, wherein the recombinant peptide or the recombinant vector allows STAT3 to be overexpressed in the mitochondria to enhance the mitochondrial function, resulting in inhibiting the expression of inflammatory cytokines including IL-17, whereby the composition may be advantageously used for preventing or treating autoimmune disease or inflammatory diseases. | 2022-08-11 |
20220251156 | ADENO-ASSOCIATED VIRUS VECTOR DELIVERY OF B-SARCOGLYCAN AND MICRORNA-29 AND THE TREATMENT OF MUSCULAR DYSTROPHY - Described herein are recombinant AAV vectors comprising a polynucleotide sequence comprising β-sarcoglycan and methods of using the recombinant vectors to reduce or prevent fibrosis in a mammalian subject suffering from a muscular dystrophy. Also described herein are combination therapies comprising administering AAV vector(s) expressing β-sarcoglycan and miR-29c to a mammalian subject suffering from a muscular dystrophy. | 2022-08-11 |
20220251157 | IgM-MEDIATED RECEPTOR CLUSTERING AND CELL MODULATION - Materials and methods for using multivalent molecules (e.g., antibodies) to modulate cellular function. A molecule can be targeted to a particular type of cell, either through direct binding to an epitope on the surface of the cell, or through a linker that recognizes both the multivalent molecule and a marker on the cell surface. | 2022-08-11 |
20220251158 | INTERMEDIATE FILAMENT-DERIVED PEPTIDES AND THEIR USES - The present invention relates to peptides derived from known intermediate filaments which are capable of inducing cell death in metazoan cells, and/or stimulating pro-inflammatory cytokine secretion. The peptides consist of a first region of “n” amino acids, wherein “n” is 0 to 41 amino acids; a second region of 9 amino acids; wherein the sequence of 9 amino acids is [(a)/(b)]-[K/R]-[(a)/(b)]-[(a)/(b)/(c)/(d)]-[L]-[(e)]-[(a)/(b)/(c)]-[E]-[I] (SEQ ID NO: 1), wherein (a) is a nonpolar aliphatic amino acid, (b) is a polar uncharged amino acid, (c) is a positively charged amino acid, (d) is an aromatic amino acid, (e) is a negatively charged amino acid; and a third region of “m” amino acids, wherein “m” is 0 to 41 amino acids. The peptides of the invention have a minimum length of 9 amino acids and a maximum length of 50 amino acids. These peptides may be useful as new adjuvants in vaccines, either alone or in combination with other therapies; as well as chemotherapeutic agents, either alone or in combination with other drugs or therapies. | 2022-08-11 |
20220251159 | PEPTIDES AND USE OF SAME IN THE TREATMENT OF DISEASES, DISRODERS OR CONDITIONS ASSOCIATED WITH A MUTANT P53 - An isolated peptide is provided. The peptide comprises an amino acid sequence arranged in a space and configuration that allow interaction of the peptide with the DNA Binding Domain (DBD) of p53 through at least one residue of the DBD by which pCAP 250 (SEQ ID NO: 1) binds the DBD, wherein the peptide at least partially reactivates a mutant p53 protein, with the proviso that the peptide is not SEQ ID NO: 59-382. | 2022-08-11 |
20220251160 | IN VIVO TARGETING OF CELLS WITH LIGAND-CONJUGATED PARTICLES - The invention provides compositions and methods for, inter alia, augmenting cell-based therapies in vivo by repeatedly stimulating target cells of interest over a period of time. | 2022-08-11 |
20220251161 | Agents and Methods for Treating Viral Infections - An interleukin which binds to IL-2 receptor (IL-2R), or a nucleotide sequence encoding therefor, wherein the interleukin or nucleotide sequence is adapted to be targeted to the liver. | 2022-08-11 |
20220251162 | PAC1 RECEPTOR AGONISTS (MAXCAPS) AND USES THEREOF - In certain embodiments novel PAC1 receptor agonists are provided wherein the agonists comprise a targeting sequence that binds to the PAC1 receptor and said targeting sequence is attached to an amino acid sequence comprising a fragment of the maxadilan amino acid sequence, wherein the targeting sequence comprises a full-length 38 amino acid PACAP peptide or an N-terminus fragment thereof containing the amino acid sequence HSDGIF, wherein said targeting sequence optionally comprises an amino acid insertion between residues 11 and 12 of said PACAP peptide or fragment thereof; and the fragment of the maxadilan amino acid sequence comprises a fragment of the maxadilan sequence effective to activate PAC1 signaling. | 2022-08-11 |
20220251163 | GIP AND GLP-1 DUAL AGONIST POLYPEPTIDE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT AND APPLICATION THEREOF - A GIP and GLP-1 dual agonist polypeptide compound, having an amino acid sequence as follows: | 2022-08-11 |
20220251164 | LONG-ACTING CONJUGATES OF GLP-2 DERIVATIVES - A glucagon-like peptide-2 (GLP-2) derivative, a conjugate thereof, and a use thereof are disclosed. Additionally, a method for preparing a glucagon-like peptide-2 (GLP-2) derivative and a conjugate thereof is disclosed. | 2022-08-11 |
20220251165 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT - The present invention provides engineered platelets with chimeric platelet receptors (CPR) with a desired target specificity. Additionally, the engineered platelets may comprise cargo which may be released upon activation of the platelet. Additionally, the platelets may be generated in vitro from megakaryocytes engineered to generate non-thrombogemc platelets. | 2022-08-11 |
20220251166 | MOLECULE SPECIFICALLY ACTING IN A TISSUE WHERE A CELL DEATH IS BEING OBSERVED - Problems to be solved An objective of the present invention is to provide a molecule which acts specifically in a tissue which is sought to be treated or targeted such as affected tissue, abnormal tissue or the like, but does not or less act in a healthy or normal tissue, which enables to provide a molecule useful for a medicament with reduced adverse effect while conferring significant therapeutic or preventive effect. | 2022-08-11 |
20220251167 | T-Cell Receptor for Treating Fibrolamellar Hepatocellular Carcinoma - A vector harboring nucleic acids encoding a recombinant T cell receptor having antigenic specificity for a DnaJ heat shock protein family member B1-protein kinase cAMP-activated catalytic subunit alpha (DNAJB1-PRKACA) fusion protein is provided, as are host cells and a method for treating fibrolamellar hepatocellular carcinoma with the vector. | 2022-08-11 |
20220251168 | Dimeric Antigen Receptors (DAR) that Bind BCMA - The present disclosure provides dimeric antigen receptors (DAR) constructs that bind a BCMA target antigen, where the DAR construct comprises a heavy chain binding region on one polypeptide chain and a light chain binding region on a separate polypeptide chain. The two polypeptide chains that make up the dimeric antigen receptors can dimerize to form an antigen binding domain. The dimeric antigen receptors have antibody-like properties as they bind specifically to a target antigen. The dimeric antigen receptors can be used for directed cell therapy. | 2022-08-11 |
20220251169 | ACTIVATABLE FUSION PROTEIN AND USE THEREOF - Disclosed herein is an activatable fusion protein that includes, in an N- to C-terminal direction, an albumin, a matrix metalloproteinase-cleavable linker, and an immunoadhesin which includes a cytotoxic T lymphocyte-associated antigen-4 (CTLA4) having an N-terminal extracellular domain and an IgG Fc region, wherein the albumin is released from the activatable fusion protein in the presence of a matrix metalloproteinase that cleaves the cleavable linker, so that the N-terminal extracellular domain of the CTLA4 binds to CD80 or CD86. Also disclosed herein is use of the activatable fusion protein for suppressing a T cell-dependent immune response. | 2022-08-11 |
20220251170 | NOVEL EXOSOME-BASED ANTICANCER AGENT - The present invention provides a recombinant exosome and uses thereof. More particularly, the present invention provides a recombinant exosome wherein a phagocytosis promoting protein is presented on the surface of the exosome. | 2022-08-11 |
20220251171 | APOLIPOPROTEIN E FRAGMENTS - The present invention relates to novel fragments of apolipoprotein E (ApoE). These ApoE fragments have a variety of uses including as components of vaccine compositions, particularly vaccines for the prevention or treatment of neurological disorders such as Alzheimer's disease. The ApoE fragments may also be used in screening methods and methods of detection. | 2022-08-11 |
20220251172 | RECOMBINANTLY ENGINEERED, LIPASE/ESTERASE-DEFICIENT MAMMALIAN CELL LINES - Mammalian cell lines with reduced expression and/or activity of lipases/esterases, and methods of producing the same are provided. Also provided are compositions comprising polysorbate and recombinant proteins produced in said mammalian cells which have improved polysorbate stability. | 2022-08-11 |
20220251173 | ANTI-HEPATITIS B VIRUS ANTIBODIES AND USE THEREOF - Antibodies (especially humanized antibodies) against the hepatitis B surface antigen (HBsAg), a nucleic acid molecule encoding same, a method for preparing same, and a pharmaceutical composition containing same. The anti-HBsAg antibodies have a higher binding affinity to HBsAg at a neutral pH than at an acidic pH, thereby significantly enhancing virus clearance efficiency and prolonging virus inhibition time. The antibodies and pharmaceutical composition may be used to prevent and/or treat HBV infections or diseases related to HBV infection (such as hepatitis B) for use in neutralizing the virulence of HBV in the body of a subject (such as a human) to reduce a serum level of HBV DNA and/or HBsAg in the body of the subject, or to activate a humoral immune response of a subject (such as a person infected with chronic HBV or a patient who has chronic hepatitis B) against HBV. | 2022-08-11 |
20220251174 | ANTI-SPIKE GLYCOPROTEIN ANTIBODIES AND THE THERAPEUTIC USE THEREOF - The present application relates to neutralizing antibodies or antigen-binding fragments thereof against betacoronaviruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), to nucleic acid(s) encoding such neutralizing antibodies or antigen-binding fragments thereof, and to mixture and compositions comprising such antibodies, antigen-binding fragments or nucleic acids. Such neutralizing antibodies or antigen-binding fragments thereof are able to block betacoronavirus entry into cells and/or to induce complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and/or antibody-dependent cellular phagocytosis (ADCP) against betacoronavirus-infected cells. Methods and uses of the antibodies, antigen-binding fragments thereof, nucleic acid(s) or compositions, including therapeutic, diagnostic, and preventative methods and uses for betacoronavirus infections and related diseases such as COVID-19, are also described. | 2022-08-11 |
20220251175 | Compositions and methods for treating and preventing staphylococcus aureus infections - Antibodies having Fab regions that specifically bind to | 2022-08-11 |
20220251176 | FUSION PROTEIN COMPRISING ANTI-MESOTHELIN ANTIBODY, ANTI-CD3 ANTIBODY OR ANTI-EGFR ANTIBODY, BISPECIFIC OR TRISPECIFIC ANTIBODY COMPRISING SAME, AND USES THEREOF - A fusion protein including a fragment of an anti-mesothelin antibody, an anti-CD3 antibody or an anti-EGFR antibody; a bispecific antibody that is specific to mesothelin and CD3; a trispecific antibody that is specific to mesothelin, CD3 and EGFR are provided. The fusion protein is effective in treating cancer. The bispecific or trispecific antibody can be prepared in a high yield and with high purity, and has excellent tumor killing and growth inhibitory effects, and thus can be effectively used in cancer treatment. | 2022-08-11 |
20220251177 | METHODS AND COMPOSITIONS RELATING TO ANTI-NUCLEOLIN RECOMBINANT IMMUNOAGENTS - Disclosed herein are methods and compositions related to single chain antibody fragments which specifically bind nucleolin (NCL). Also disclosed are treating and diagnosing diseases using single chain antibody fragments that bind nucleolin. | 2022-08-11 |
20220251178 | TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIESHEREOF - Methods for immediate relief of migraine or headache are provided comprising the administration of an anti-CGRP antagonist antibody to a patient in need thereof. This invention pertains to methods of treatment of headache disorders, such as migraine, using antibodies and fragments thereof (including Fab fragments) that specifically bind to human Calcitonin Gene Related Peptide (hereinafter “CGRP”). | 2022-08-11 |
20220251179 | COMPOSITION AND METHODS TO TREAT ECTODERMAL DYSPLASIA 2, CLOUSTON TYPE - The present technology relates generally to compositions and methods of preventing or treating diseases associated with mutant Cx26, Cx32, and/or Cx30 hemichannels. The present technology also relates to administering the anti-Cx26 hemichannel antibodies in effective amounts to treat a subject suffering from, or predisposed to, ectodermal dysplasia 2, Clouston type (OMIM No. 129500), Keratitis-ichthyosis-deafness syndrome (KIDS; OMIM No. 148210), and/or type X Charcot-Marie-Tooth neuropathy (CMTXl; OMIM No. 302800). | 2022-08-11 |
20220251180 | ANTI-APOC3 ANTIBODIES - The instant disclosure provides antibodies that specifically bind to ApoC3 (e.g., human ApoC3) and antagonize ApoC3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies. | 2022-08-11 |
20220251181 | ANTIBODIES TO AMYLOID BETA - Antibody for human amyloid beta. Antibody selectively binds human amyloid beta 42 peptide over human amyloid beta 40 peptide. Antibodies specific for amyloid beta 42 as therapeutic agents for binding amyloid beta 42 peptide and treating conditions associated with amyloidosis, such as Alzheimer's disease. | 2022-08-11 |
20220251182 | AGENTS WHICH INHIBIT GADS DIMERIZATION AND METHODS OF USE THEREOF - Agents which inhibit Gads dimerization are provided. Accordingly there is provided an agent which inhibits Gads (SEQ ID NO: 1) dimerization, the agent interacting with a pharmacophore binding site comprising an amino acid selected from the group consisting of F55, P56, W58, F59, E61, G62, A84-F92, V107-N111, Y115, F116, L125 and N126 of SEQ ID NO: 1. Also provided an agent which inhibits Gads (SEQ ID NO: 1) dimerization, the agent interacting with a pharmacophore binding site comprising an amino acid sequence of an SH3 domain of SEQ ID NO: 1. Also provided are methods of inhibiting activation of a T cell and/or a mast cell and methods of treating or preventing a disease associated with activation of T cells or an allergic response. | 2022-08-11 |
20220251183 | IMMUNOGLOBULIN VARIABLE DOMAINS - VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I). | 2022-08-11 |
20220251184 | HUMAN ANTIBODIES TO BONE MORPHOGENETIC PROTEIN 6 - The present invention provides antibodies that bind to BMP6, and methods of use. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to BMP6. The antibodies of the invention are useful for inhibiting binding of BMP6 to the hemojuvelin receptor, thereby down-regulating transcription and expression of hepcidin, thus providing a means of preventing or treating an iron-deficiency anemia or an iron-deficiency related disorder. In some embodiments, the antibodies of the present invention are used in treating at least one symptom or complication of an iron-deficiency anemia or an iron-deficiency related disorder. | 2022-08-11 |
20220251185 | HYDROPHILIC LINKERS FOR MULTIVALENT PEPTIDE CONJUGATES - The present disclosure is directed to peptide-polymer conjugates utilizing hydrophilic linkers, and their use in treating diseases or disorders. In one embodiment, the present invention provides a conjugate of Formula I: (X—Y)n-Z Formula (I) wherein each X is independently a peptide having a molecular weight of from about 5 kDa to about 200 kDa; each Y is independently a hydrophilic linker; Z is a biocompatible polymer having a molecular weight of from about 0.1 MDa to about 3 MDa; and subscript n is an integer from 10 to 1000. | 2022-08-11 |
20220251186 | AGENTS THAT INTERFERE WITH THYMIC STROMAL LYMPHOPOIETIN (TSLP)-RECEPTOR SIGNALING - The present disclosure is related to antibodies (e.g., human antibodies) and antigen-binding fragments thereof that specifically bind and neutralize (human) thymic stromal lymphopoietin (TSLP). Such molecules may have modified F | 2022-08-11 |
20220251187 | P2X7 RECEPTOR TARGETED THERAPY - The invention relates to methods of treating cancer, particular cancers which have developed a resistance to chemotherapeutics. Particularly, the invention relates to a method of treating cancer in an individual who has not responded, or no longer responds, to chemotherapy, the method comprising providing an individual who has not responded, or no longer responds, to a chemotherapeutic agent; providing in the individual a whole antibody or a fragment thereof including a variable domain for binding to a P2X7 receptor that is expressed by the individual; wherein the P2X7 receptor has an impaired response to ATP such that it is unable to form an apoptotic pore under normal physiological conditions, thereby treating cancer in the individual. | 2022-08-11 |
20220251188 | FORMULATION COMPRISING ANTI-LAG-3 ANTIBODY, METHOD FOR PREPARING SAME AND USE THEREOF - The present invention relates to formulations comprising an anti-LAG-3 antibody, and in particular to pharmaceutical formulations comprising an antibody specifically binding to LAG-3 molecules, a buffer, a stabilizer and a surfactant. Furthermore, the present invention also relates to therapeutic or prophylactic use of these formulations. | 2022-08-11 |
20220251189 | BINDING MOLECULE SPECIFIC FOR LRIG-1 PROTEIN AND USE THEREOF - The present invention relates to a binding molecule capable of specifically binding to Lrig-1 protein, which is located on the surface of a regulatory T cell. The binding molecule provided in the present invention can activate the function of regulatory T cells to effectively prevent, ameliorate, or treat diseases caused by excessive activation or expression of various immune cells and inflammatory cells, for example, immune-related diseases such as autoimmune disease, graft-versus-host disease, organ transplant rejection, asthma, atopy, acute or chronic inflammatory disease, etc. In addition, the binding molecule, preferably the antibody, specific for the Lrig-1 protein according to the present invention has advantages of more effectively targeting the Lrig-1 protein as compared with antibodies against Lrig-1 which are previously commercially available, and also possessing very good binding capacity thereto. | 2022-08-11 |
20220251190 | ANTI-CD33 ANTIBODIES AND METHODS OF USE THEREOF - The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof. | 2022-08-11 |
20220251191 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING CANCER IN COMBINATION WITH ANALOGS OF INTERLEUKIN PROTEINS - Provided are compositions and methods for treating cancer by administering antiCD47 mAbs and anti-CD47 fusion proteins with distinct functional profiles or chimeric antigen receptor (CAR)-bearing immune effector cells in combination with analogs of interleukin proteins. | 2022-08-11 |
20220251192 | ANTI-CD33 ANTIBODIES FOR TREATING CANCER - The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to the CDS 3 protein. The antibodies of the present technology are useful in methods for detecting and treating Alzheimer's disease or a CD33-associated cancer in a subject in need thereof. | 2022-08-11 |
20220251193 | SEMAPHORIN 3A ANTIBODIES AND USES THEREOF - Antibodies comprising an antigen recognition region which binds a semaphorin 3A (Sema3A) are disclosed. Uses thereof are also disclosed. | 2022-08-11 |
20220251194 | ANTI-PD-1/LAG3/TIGIT TRISPECIFIC ANTIBODIES AND ANTI-PD-1/LAG3 BICPECIFIC ANTIBODIES - Provided herein are treatments of conditions ameliorated by counteracting tumor mediated immune suppression. More specifically, provided herein are anti-PD-1/LAG-3/TIGIT trispecific antibodies, anti-PD-1/LAG3 bispecific antibodies, anti-LAG3 antibodies and antigen-binding fragments. Also provided here are methods and uses of these antibodies and antigen-binding fragments in the treatment of cancer or infectious disease. | 2022-08-11 |
20220251195 | ANTI-TIGIT ANTIBODIES AND THEIR USE AS THERAPEUTICS AND DIAGNOSTICS - Provided are antibodies that specifically bind to TIGIT (T cell immunoreceptor with Ig and ITIM domains, WUCAM or Vstm3) and inhibit Tigit-mediated cellular signaling and activities in immune cells. The anti-TIGIT antibodies can be used to treat or diagnose cancer, infectious diseases or other pathological disorders that may be modulated by Tigit-mediated functions. | 2022-08-11 |
20220251196 | Low dose antibody-based methods for treating hematologic malignancies - This invention provides a method for treating a subject afflicted with a hematologic malignancy comprising administering to the subject an agent targeting a hematologic malignancy-associated antigen, wherein the subject has a low peripheral cancerous cell burden. This invention also provides a method for treating a subject afflicted with a hematologic malignancy and having a high peripheral cancerous cell burden, comprising (i) medically lowering the subject's peripheral cancerous cell burden, and (ii) while the subject's peripheral cancerous cell burden is still low, administering to the subject an agent targeting a hematologic malignancy-associated antigen. Particularly envisioned are the subject methods for treating acute myeloid leukemia using an anti-CD33 antibody labeled with an alpha-emitting isotope, such as | 2022-08-11 |